{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:44:36Z","timestamp":1789577076005,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We here report on a patient with relapsed-refractory multiple myeloma (RRMM) who received chimeric antigen receptor (CAR) T-cells (Ciltacabtagene Autoleucel, cilta-cel, Carvykti<jats:sup>\u00ae<\/jats:sup>) after achieving a partial but not durable remission with Idecabtagene Vicleucel (ide-cel, Abecma<jats:sup>\u00ae<\/jats:sup>). Both CAR T-cells target the B-cell maturation antigen (BCMA) and their sequential use is as yet rare, thus data on safety and efficacy of their sequential employment are precious and relevant for the myeloma commmunity.<\/jats:p>","DOI":"10.1007\/s00277-025-06340-y","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:48:00Z","timestamp":1743785280000},"page":"2055-2058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Paul","family":"Mobascher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"5","key":"6340_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ejh.13690","volume":"107","author":"C Straka","year":"2021","unstructured":"Straka C, Salwender H, Knop S et al (2021) Full or intensity-reduced high-dose Melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. Eur J Haematol 107(5):529\u2013542","journal-title":"Eur J Haematol"},{"issue":"1","key":"6340_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00390-3","volume":"11","author":"M-A Baertsch","year":"2021","unstructured":"Baertsch M-A, Mai EK, Hielscher T et al (2021) Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J 11(1):1","journal-title":"Blood Cancer J"},{"issue":"1","key":"6340_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos M-V et al (2022) Carfilzomib, dexamethasone, and daratumumab versus Carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 23(1):65\u201376","journal-title":"Lancet Oncol"},{"issue":"5","key":"6340_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/14737140.2024.2343114","volume":"24","author":"S Elemian","year":"2024","unstructured":"Elemian S, Al Hadidi S (2024) Targeting GPRC5D in multiple myeloma. Expert Rev Anticancer Ther 24(5):229\u2013238","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"6340_CR5","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S et al (2018) Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379(19):1811\u20131822","journal-title":"N Engl J Med"},{"issue":"3","key":"6340_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00277-022-05051-y","volume":"102","author":"B Frank","year":"2023","unstructured":"Frank B, Ihorst G, Herget G et al (2023) Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers. Ann Hematol 102(3):603\u2013611","journal-title":"Ann Hematol"},{"issue":"1","key":"6340_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H et al (2023) Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J 13(1):117","journal-title":"Blood Cancer J"},{"issue":"3","key":"6340_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC et al (2023) Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141(3):219\u2013230","journal-title":"Blood"},{"issue":"23","key":"6340_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P et al (2024) Efficacy and safety of Teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood 144(23):2375\u20132388","journal-title":"Blood"},{"issue":"4","key":"6340_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via MC, Dietrich O, Truger M et al (2021) Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 27(4):616\u2013619","journal-title":"Nat Med"},{"issue":"1","key":"6340_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Samur AA et al (2021) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Comm 12(1):868","journal-title":"Nat Comm"},{"issue":"9","key":"6340_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R et al (2023) Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29(9):2295\u20132306","journal-title":"Nat Med"},{"issue":"11","key":"6340_CR13","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","volume":"4","author":"J Derrien","year":"2023","unstructured":"Derrien J, Gastineau S, Frigout A et al (2023) Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer 4(11):1536\u20131543","journal-title":"Nat Cancer"},{"issue":"1","key":"6340_CR14","doi-asserted-by":"publisher","first-page":"e70070","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici A-M, von Tresckow B et al (2025) Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. HemaSphere 9(1):e70070","journal-title":"HemaSphere"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06340-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06340-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:49Z","timestamp":1745575849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06340-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6340"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06340-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient included in the case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"MP: no competing interests. ME: consulted for and\/or received honoraria from Amgen, BMS, GSK, Johnson & Johnson, Pfizer, Sanofi, Stemline, Takeda and received research funding from BMS, Johnson&Johnson and Pfizer all paid to UKF. RW consulted for and\/or received honoraria from Abbvie, Alexion, Amgen, BMS, Johnson & Johnson, Kite\/Gilead, Novartis, Pfizer, Sanofi, Takeda and received research funding from Johnson & Johnson and Sanofi all paid to UKF.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}